AbbVie Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 26/100
What the filing says
AbbVie Inc. entered into an underwriting agreement dated August 4, 2026, to issue $9.0 billion in senior notes across nine tranches: $500M floating-rate (2028), $1.0B at 4.500% (2028), $1.25B at 4.650% (2030), $1.5B at 4.875% (2031), $1.25B at 5.050% (2033), $1.5B at 5.300% (2036), $1.0B at 5.450% (2038), $1.5B at 6.000% (2056), and $500M at 6.100% (2066). Lead underwriters: Morgan Stanley, BofA Securities, J.P. Morgan, and SG Americas. Closing scheduled August 18, 2026.
Why this rating
Standard debt issuance; $9B is ~2.8% of $325B market cap, routine financing activity for large pharmaceutical firm.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.